Danaher Corporation to Buy Aldevron
Posted on 06/18/2021
Danaher Corporation entered into a definitive agreement to acquire privately-held Aldevron, LLC, for a cash purchase price of approximately US$ 9.6 billion. Danaher expects to finance the acquisition using cash on hand and/or proceeds from the issuance of commercial paper. EQT Private Equity is selling Aldevron after acquiring a controlling stake in 2019.
Founded in 1998 by Michael Chambers and John Ballantyne, Aldevron is headquartered in Fargo, North Dakota and employs approximately 600 people. Aldevron manufactures high-quality plasmid DNA, mRNA, and proteins, serving biotechnology and pharmaceutical customers across research, clinical and commercial applications. Aldevron will operate as a standalone operating company and brand within Danaher’s Life Sciences segment.
The transaction is subject to customary conditions, including receipt of applicable regulatory approvals.
